Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.